Arch Cancer Therapeutics, Inc.

Arch Biopartners, Inc.

Uti Limited Partnership

Stephen Mark Robbins

Jennifer Joy Rahn

Donna Lorraine Senger

Paul Kubes

Daniel Abraham Muruve

Arthur Wing Sze Lau

Saurav Roy Choudhury

Liane Babes

Elizabeth M Long

Ela Kolaczkowska

Justin MacDonald

Donnal Lorraine Senger

Donnal Lorriane Senger

Jennifer Rahn

Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.

DPEP-1 binding compositions and methods of use

DPEP-1 binding agents and methods of use

Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.

Peptides that block leukocyte recruitment and methods of use

The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammatory function, while the GM1-binding peptide facilitates endocytosis.

Modified toll-like receptor 2 (TLR2) ligands as inhibitors of neutrophil recruitment

A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).

Brain tumor targeting peptides and methods

A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). Also disclosed are a phage-display screening method for identifying such therapeutic peptides, and peptides that hind specifically to BTICs or HIGCs.

Growing community of inventors

Calgary, Canada

Stephen Mark Robbins